Jordan R Smith1, Katie E Barber1, Animesh Raut1, Mostafa Aboutaleb1, George Sakoulas2, Michael J Rybak3. 1. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA. 2. University of California San Diego School of Medicine, La Jolla, CA, USA University of California San Diego Division of Biology, La Jolla, CA, USA. 3. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA Wayne State University School of Medicine, Detroit, MI, USA aa1592@wayne.edu.
Abstract
OBJECTIVES: Enterococcus faecalis (Efc) and Enterococcus faecium (Efm) are frequently resistant to vancomycin and β-lactams (BLs). In vitro data suggest synergy between several BLs and glycopeptides or lipopeptides against resistant pathogens. Our objective was to conduct combination MIC and time-kill experiments to evaluate BL synergy with daptomycin against enterococci. METHODS: Fifteen Efc and 20 Efm strains were evaluated for daptomycin enhancement via combination MICs. Daptomycin MICs were obtained by microdilution in the absence and presence of ceftaroline, ertapenem, cefepime, ceftriaxone, cefotaxime, cefazolin and ampicillin. Two Efc strains (R6981 and R7808) and one isogenic daptomycin-susceptible/daptomycin-non-susceptible Efm pair (8019/5938) were evaluated in time-kill experiments. Daptomycin at 0.5 × MIC was used in combination with BL at biological free concentration. Strain 5938 was evaluated for enhancement of daptomycin binding in fluorescently labelled daptomycin (BoDipy) experiments. RESULTS: Ceftaroline reduced daptomycin MIC values the most against all strains. In time-kill experiments, ceftaroline, ertapenem, cefepime, ceftriaxone and ampicillin demonstrated synergy with daptomycin against all strains, cefazolin demonstrated none and cefotaxime demonstrated synergy against only R7808. Bacterial reduction at 24 h was greater for daptomycin + ceftaroline, ertapenem, cefepime, ceftriaxone or ampicillin for all strains compared with any single agent or daptomycin + cefazolin or cefotaxime (P < 0.001). In BoDipy daptomycin experiments, ceftaroline enhanced daptomycin binding most compared with all other agents (P < 0.001). CONCLUSIONS: The data support the potential use of daptomycin/BL combination therapy in infections caused by VRE. Combination regimens, other than those involving cefazolin and cefotaxime, provide better kill compared with daptomycin alone. Further clinical research involving daptomycin combinations is warranted.
OBJECTIVES:Enterococcus faecalis (Efc) and Enterococcus faecium (Efm) are frequently resistant to vancomycin and β-lactams (BLs). In vitro data suggest synergy between several BLs and glycopeptides or lipopeptides against resistant pathogens. Our objective was to conduct combination MIC and time-kill experiments to evaluate BL synergy with daptomycin against enterococci. METHODS: Fifteen Efc and 20 Efm strains were evaluated for daptomycin enhancement via combination MICs. Daptomycin MICs were obtained by microdilution in the absence and presence of ceftaroline, ertapenem, cefepime, ceftriaxone, cefotaxime, cefazolin and ampicillin. Two Efc strains (R6981 and R7808) and one isogenic daptomycin-susceptible/daptomycin-non-susceptible Efm pair (8019/5938) were evaluated in time-kill experiments. Daptomycin at 0.5 × MIC was used in combination with BL at biological free concentration. Strain 5938 was evaluated for enhancement of daptomycin binding in fluorescently labelled daptomycin (BoDipy) experiments. RESULTS:Ceftaroline reduced daptomycin MIC values the most against all strains. In time-kill experiments, ceftaroline, ertapenem, cefepime, ceftriaxone and ampicillin demonstrated synergy with daptomycin against all strains, cefazolin demonstrated none and cefotaxime demonstrated synergy against only R7808. Bacterial reduction at 24 h was greater for daptomycin + ceftaroline, ertapenem, cefepime, ceftriaxone or ampicillin for all strains compared with any single agent or daptomycin + cefazolin or cefotaxime (P < 0.001). In BoDipydaptomycin experiments, ceftaroline enhanced daptomycin binding most compared with all other agents (P < 0.001). CONCLUSIONS: The data support the potential use of daptomycin/BL combination therapy in infections caused by VRE. Combination regimens, other than those involving cefazolin and cefotaxime, provide better kill compared with daptomycin alone. Further clinical research involving daptomycin combinations is warranted.
Authors: L B Rice; L L Carias; R Hutton-Thomas; F Sifaoui; L Gutmann; S D Rudin Journal: Antimicrob Agents Chemother Date: 2001-05 Impact factor: 5.191
Authors: Lorena Diaz; Truc T Tran; Jose M Munita; William R Miller; Sandra Rincon; Lina P Carvajal; Aye Wollam; Jinnethe Reyes; Diana Panesso; Natalia L Rojas; Yousif Shamoo; Barbara E Murray; George M Weinstock; Cesar A Arias Journal: Antimicrob Agents Chemother Date: 2014-05-27 Impact factor: 5.191
Authors: Ravina Kullar; Anthony M Casapao; Susan L Davis; Donald P Levine; Jing J Zhao; Christopher W Crank; John Segreti; George Sakoulas; Sara E Cosgrove; Michael J Rybak Journal: J Antimicrob Chemother Date: 2013-08-08 Impact factor: 5.790
Authors: Ashley Hall Snyder; Brian J Werth; Katie E Barber; George Sakoulas; Michael J Rybak Journal: J Antimicrob Chemother Date: 2014-04-28 Impact factor: 5.790
Authors: E O Billington; S H Phang; D B Gregson; J D D Pitout; T Ross; D L Church; K B Laupland; M D Parkins Journal: Int J Infect Dis Date: 2014-05-09 Impact factor: 3.623
Authors: Xavier Henry; Oliver Verlaine; Ana Amoroso; Jacques Coyette; Jean-Marie Frère; Bernard Joris Journal: Antimicrob Agents Chemother Date: 2013-09-23 Impact factor: 5.191
Authors: Razieh Kebriaei; Seth A Rice; Kyle C Stamper; Ravin Seepersaud; Cristina Garcia-de-la-Maria; Nagendra N Mishra; Jose M Miro; Cesar A Arias; Truc T Tran; Paul M Sullam; Arnold S Bayer; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Razieh Kebriaei; Jordan R Smith; Katherine Lev; T T Tran; Warren E Rose; Cesar A Arias; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191